Fatal acute respiratory distress syndrome with diffuse alveolar damage: donor lymphocyte infusion imputability?. Issue 6 (1st September 2016)

• Record Type: Journal Article
• Authors: Saillard, Colombe; Bisbal, Magali; Sannini, Antoine; Chow-Chine, Laurent; Brun, Jean-Paul; Harbi, Samia; Furst, Sabine; Blaise, Didier; Paciencia, Maria; Secq, Véronique; Mokart, Djamel
• Is Part Of: European respiratory journal. Volume 48:Issue 6(2016)
• Page Start: 1794
• Page End: 1796
• Publication Date: 2016-09-01
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.01130-2016
• Languages: English
• ISSNs: 0903-1936

Abstract

Donor lymphocyte infusion (DLI) is increasingly used after allogeneic haematopoietic stem cell transplantation (allo-HSCT), as a pre-emptive or curative immunotherapy of relapsed haematological malignancies, enhancing graft- versus -tumour effects [1]. The main complication is graft- versus -host disease (GVHD), with cumulative incidences of 40–60% and 33–61% for acute and chronic GVHD, respectively, typically developing 32–42 days after DLI [2]. Pulmonary complications after DLI are poorly documented. To our knowledge, there are no cases of diffuse alveolar damage (DAD) [3] after DLI in the literature to date. Here, we report our experience of two cases of acute respiratory distress syndrome (ARDS) with DAD following DLI after allo-HSCT, rapidly extending to fatal pulmonary fibrosis. Submission was approved by our institutional review board and informed consent was obtained. Fatal ARDS with diffuse alveolar damage: donor lymphocyte infusion imputability? http://ow.ly/WhxP3034P6s